Antibody Screen, RBC with Reflex to Identification, Titer, and Antigen Typing
The RBC Antibody Screen with Reflex detects circulating red-cell alloantibodies and autoantibodies via indirect antiglobulin test; positive results trigger automatic identification of antibody specificity, quantification by titre, and red-cell phenotyping.
4
Biomarkers
Blood (whole blood)
Sample
3–5 business days
Turnaround
No
Fasting
What is the RBC Antibody Screen (Reflex) test?
The RBC Antibody Screen with Reflex to Identification, Titer, and Antigen Typing is a tiered immunohaematology cascade designed to detect, characterise, and quantify red-cell alloantibodies and autoantibodies. The initial screen uses the indirect antiglobulin test to detect circulating antibodies; if positive, the laboratory reflexes without a second order to identify the antibody specificity, quantify its titre, and phenotype the patient's red cells for the relevant antigens. This single orderable captures the full workup needed for safe transfusion and obstetric alloimmunisation management. Practitioners order this cascade before transfusion in patients with a history of antibodies or obstetric alloimmunisation, for unexplained transfusion reactions or haemolysis, and for pregnant patients whose initial screen is positive or who carry known antibodies. The reflex structure ensures that a positive screen is not left incomplete — identification, titre, and phenotype follow automatically, providing the blood bank and obstetric team with actionable data in a single result set.
What does the RBC Antibody Screen (Reflex) test measure?
The immune system can form IgG or IgM antibodies against red blood cell antigens following exposure through transfusion, pregnancy, or haemolytic disease. The indirect antiglobulin test (IAT) detects these circulating antibodies by incubating patient serum with a panel of reagent red cells carrying known antigens; agglutination after adding anti-human globulin indicates the presence of an antibody. Most clinically significant antibodies are IgG and react at 37°C or in the IAT phase, targeting antigens in systems such as Rh, Kell, Duffy, Kidd, or S/s.
A positive screen triggers a reflex cascade to identify the specific antibody, quantify its titre (a measure of concentration and clinical significance), and determine which red-cell antigens the patient carries. This information is critical for safe transfusion — antigen-negative blood must be selected — and for obstetric management, since maternal IgG antibodies can cross the placenta and cause haemolytic disease of the fetus and newborn.
Antibody identification uses an extended panel of reagent cells with defined antigen phenotypes. By observing which cells react and which do not, the blood bank determines the specificity — for example, anti-K reacts only with Kell-positive cells. Some patients form multiple antibodies, and warm autoantibodies or cold agglutinins can complicate the pattern.
Knowing the antibody identity allows selection of antigen-negative donor units, predicts risk in pregnancy (anti-D, anti-c, and anti-K are the most common causes of severe haemolytic disease of the newborn), and guides further workup when autoantibodies or complex mixtures are present.
The titre measures how many serial dilutions of patient serum still react with antigen-positive red cells. A titre of 1:16 means the serum reacts at a dilution of one part serum to fifteen parts saline. Higher titres reflect greater antibody concentration and, in obstetrics, correlate with increased risk of haemolytic disease, though the critical titre threshold differs by antibody and institution.
In pregnancy, serial titres track antibody rise; a fourfold increase or crossing a critical titre (commonly ≥1:16 for anti-D or anti-K) triggers middle cerebral artery Doppler surveillance and, if indicated, intrauterine transfusion. For transfusion candidates, the titre helps judge clinical significance, particularly for antibodies of uncertain pathogenicity.
Red-cell antigen typing determines which antigens the patient's own cells carry, using antisera or molecular methods to test for Rh (D, C, E, c, e), Kell, Duffy, Kidd, S/s, and other systems. Knowing the patient phenotype clarifies which antibodies are alloantibodies (directed against foreign antigens) versus autoantibodies (against self) and informs compatibility when the patient requires transfusion in future.
Antigen typing is performed to select antigen-matched units for patients with multiple antibodies or sickle-cell disease, to determine Rh and Kell status in obstetric alloimmunisation, and to differentiate allo- from autoantibody. It also guides prophylactic matching to prevent further alloimmunisation in chronically transfused patients.
Why is the RBC Antibody Screen (Reflex) test ordered?
- Pre-transfusion antibody screening in patients with prior transfusion or pregnancy, particularly those with a history of red-cell alloantibodies or unexplained reactions
- Antenatal antibody screening in pregnant patients when the initial screen is positive, or serial monitoring of known alloantibodies to track titre and guide fetal surveillance
- Investigation of suspected delayed haemolytic transfusion reactions, unexplained anaemia, or positive direct antiglobulin test (Coombs test) to detect alloantibodies or autoantibodies
- Pre-operative or pre-procedural workup in patients with sickle-cell disease or thalassaemia, who are at high risk of alloimmunisation and may require extended antigen matching
- Evaluation of haemolytic disease of the fetus and newborn when maternal antibodies other than anti-D are suspected or when anti-D titre monitoring is indicated
- Compatibility assessment for patients with multiple antibodies or a complex transfusion history, where identification, titre, and phenotype are all needed for safe blood selection
- Workup of immune haemolytic anaemia when both alloantibodies and warm or cold autoantibodies may be present, requiring antibody identification and red-cell phenotyping to untangle the picture
Sample collection and turnaround
Sample type
Blood (whole blood)
Fasting required
No
Collection method
Venipuncture at patient service centre
Turnaround
3–5 business days
Collection notes
Phlebotomy via Quest draw site. Collect in EDTA (lavender-top) or clot (red-top) tube per laboratory protocol; EDTA is often preferred for phenotyping. Label with two patient identifiers and the date and time of draw, following strict transfusion-medicine identification procedures. Ideally, obtain the specimen before transfusion to ensure accurate phenotyping; if recent transfusion has occurred, note the date and number of units, as donor cells can interfere with typing for up to three months.
Specimen requirements
Minimum 5–7 mL whole blood (EDTA or clot, per Quest protocol). Fresh specimen preferred; antibodies are most stable within 48–72 hours of draw. Reflex identification, titre, and phenotyping are performed automatically by the reference laboratory if the screen is positive; no additional order is needed.
What can affect RBC Antibody Screen (Reflex) results?
Transfused donor red cells carrying foreign antigens can confound phenotyping, and newly formed antibodies may not yet be detectable; ideally, phenotype before transfusion or wait three months after the last unit for accurate typing.
Autoantibodies can mask underlying alloantibodies or cause panreactivity on the screening and identification panels, requiring adsorption studies or other specialised techniques to reveal the alloantibody specificity.
High-dose corticosteroids, rituximab, or primary immunodeficiency can suppress antibody formation or cause titre to fall, potentially underestimating clinical risk in pregnancy or transfusion.
IVIG preparations may contain passively acquired antibodies — including anti-A, anti-B, or rarely other specificities — that can appear in the patient's serum and complicate the antibody screen and identification for several weeks.
Prolonged storage or inadequate anticoagulation can degrade antibodies or cause spontaneous agglutination, leading to false-negative screens or uninterpretable panels; fresh specimens (ideally <72 hours) are preferred.
Sample mix-up or clerical error can lead to incorrect phenotype or antibody assignment; strict two-identifier labelling and repeat typing on a second specimen are standard safeguards in transfusion medicine.
What do RBC Antibody Screen (Reflex) results mean?
Elevated
Not applicable to this cascade — results are reported as negative or positive (with reflex), antibody specificity, titre as a reciprocal dilution, and phenotype as antigen-positive or -negative, rather than as elevated or reduced numerical values.
Normal
Negative antibody screen: no clinically significant red-cell antibodies detected. This result clears the patient for transfusion of ABO/Rh-compatible blood and, in pregnancy, indicates no current risk of alloimmune haemolytic disease (though repeat screening in later trimesters remains standard antenatal practice).
Reduced
Not applicable; antibody titre may fall over time in the absence of re-exposure, but a declining titre does not equate to 'low' in the sense of a deficiency.
Note: A negative screen does not exclude all antibodies — low-titre or antibodies to low-incidence antigens may be missed. Positive results require full interpretation of the reflex identification, titre, and phenotype by a transfusion-medicine specialist or blood bank; the clinical significance of an antibody depends on its specificity, titre, and the clinical scenario (transfusion versus pregnancy). Some antibodies (anti-Lea, anti-M at room temperature) are rarely clinically significant, while others (anti-D, anti-K, anti-c, anti-Jka) can cause severe haemolysis or haemolytic disease of the newborn. Serial titres in pregnancy should be compared in the same laboratory using the same method, and a fourfold rise or crossing the critical titre threshold triggers enhanced fetal monitoring.
Frequently asked questions
The antibody screen is a qualitative test that detects whether any clinically significant red-cell antibodies are present. If positive, antibody identification uses an extended panel of reagent cells to determine the specific antibody — for example, anti-K or anti-D — so that antigen-negative blood can be selected.
How to access the RBC Antibody Screen (Reflex) test
The RBC Antibody Screen (Reflex) reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- American Association of Blood Banks (AABB) Technical Manual, 20th edition. Standards for immunohaematology reference laboratories. (2020)
- Royal College of Obstetricians and Gynaecologists. The management of women with red cell antibodies during pregnancy (Green-top Guideline No. 65). (2014)
- Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline: Management of red cell alloimmunization in pregnancy. (2022)
- Moise KJ Jr. Fetal anaemia due to non-Rhesus-D red-cell alloimmunisation. Semin Fetal Neonatal Med. (2008)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.